INFLAMMATION CLINICAL TRIAL SERVICES: PSORIASIS PROGRAM CASE STUDY Situation A pharmaceutical company needed to deliver a successful large global psoriasis program investigating the safety and efficacy of a selective immunomodulating anti-psoriatic drug that blocks the LFA-3/CD2 interaction. In addition to early development studies in animals, Covance conducted eight studies over a six-year time period, enrolling more than 2,000 patients. Our

Join for free to read